Get started
Author

S-T. Pang

LBA6 Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)
2025 · S.T. Tagawa, O. Sartor, et al. · Annals of Oncology · 50
PDF
41 Genome-wide mutational signatures of aristolochic acid in urothelial cancer
2014 · S.L. Poon, S-T. Pang, et al. · European Urology Supplements · 2
Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT+ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)
2026 · S Tagawa, O Sartor, et al. · Nuklearmedizin - NuclearMedicine
487O Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): Phase III CAPItello-281 Chinese subgroup analysis
2025 · W. Chen, D. Ye, et al. · Annals of Oncology
258MO Niraparib plus abiraterone acetate plus prednisone (NIRA+AAP) as first-line treatment in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC): Second interim analysis in the Asian subgroup of the MAGNITUDE study
2023 · M. Saad, K.N. Chi, et al. · Annals of Oncology
PDF
Using deep learning based model for detection of urolithiasis on plain X-ray of abdomen
2023 · J. Chen, S-T. Pang, et al. · European Urology
158MO Niraparib with abiraterone acetate and prednisone (NIRA+AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR+) gene alterations: Asian subgroup analysis of the MAGNITUDE study
2022 · M. Binti Saad, K.N. Chi, et al. · Annals of Oncology
PDF
Works count: 7
Citation count: 52
H-index: 2
I10-index: 1
Year
Topic
Type